Array Biopharma (ARRY) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $8.54 --0%
Revenue Growth %: -11.6%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: -11.6%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $33.28 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- FirstCash to acquire UK pawn operator Ramsdens for £206 million
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
